Understanding CLN13 Disease

Receiving a diagnosis of CLN13, also referred to clinically as Kufs disease type B, often comes after years of searching for answers ^[1][2]. Because this condition is exceptionally rare and begins in adulthood, the diagnosis can take years as it is frequently mistaken for more common neurological or psychiatric disorders ^[3][4]. Understanding this disease starts with recognizing it as a specific, progressive type of neuronal ceroid lipofuscinosis (NCL)—a group of disorders often collectively called Batten disease—that uniquely affects adults ^[5][6].

Defining CLN13

CLN13 is a neurodegenerative condition, meaning it causes the progressive loss of structure or function of neurons in the brain ^[6]. It is most frequently caused by pathogenic variants in the CTSF gene ^[5]. This gene provides instructions for making an enzyme called cathepsin F, which acts like a recycling center within cells to break down waste ^[5]. When this enzyme doesn’t work correctly, waste materials called ceroid and lipofuscin build up inside brain cells, eventually leading to cell damage and the symptoms of the disease ^[5][6].

Unlike childhood forms of Batten disease, which often begin with rapid vision loss, individuals with CLN13 usually have relatively preserved vision ^[7][8]. While visual symptoms do not independently rule out CLN13, the absence of early vision problems in an adult experiencing new neurological symptoms is often a supportive clue that points doctors toward a Kufs disease phenotype ^[7][9].

The Long Path to Diagnosis

Because symptoms appear in adults—typically between the ages of 20 and 50—doctors may first suspect more common conditions before considering a rare genetic disorder ^[2][4]. CLN13 can mimic:

• Early-onset Alzheimer’s disease: Due to progressive memory loss and cognitive decline ^[3].
• Frontotemporal dementia (FTD): Because it often begins with personality changes or behavioral shifts ^[2].
• Parkinson’s disease: Due to motor symptoms like tremors, stiffness, or slowed movement (parkinsonism) ^[2][4].
• Psychiatric disorders: Early symptoms may include depression or obsessive-compulsive behaviors before physical symptoms become obvious ^[10].

It is not uncommon for families to see different specialists over a period of years before comprehensive genetic testing identifies the underlying cause ^[1][4].

Clinical Features and Progression

CLN13 is characterized by a combination of cognitive and physical changes. While the order and severity of symptoms vary widely from person to person, the condition typically involves:

• Dementia and Cognitive Decline: This often includes “frontal” features, such as changes in judgment, social behavior, and personality ^[4][2].
• Movement Disorders: You may notice ataxia (clumsiness or loss of coordination), tremors, or muscle rigidity ^[4][11].
• Myoclonus and Seizures: Some individuals experience myoclonus (sudden, involuntary muscle jerks) or various types of seizures, though these do not happen to everyone ^[1][5].
• Motor Progression: Over time, the disease can lead to significant difficulty with speech and movement, sometimes progressing to a state called akinetic mutism, a profound impairment in initiating movement or speech ^[4].

Managing a Rare Adult NCL

There is currently no approved disease-modifying therapy or cure for CLN13, and treatments specifically targeting the CTSF gene are not currently available in practice ^[12]. Instead, care focuses on managing symptoms, ensuring safety, and maintaining the best possible quality of life ^[13][14].

Standard care involves a multidisciplinary team—a group of specialists working together to address different needs ^[13]. This often includes:

1. Neurologists to manage seizures and movement symptoms ^[14].
2. Genetic Counselors to help the family understand the inheritance pattern and risks for relatives ^[5].
3. Physical and Occupational Therapists to assist with mobility, positioning, and safety ^[15].
4. Speech-Language Pathologists to help with communication and monitor for swallowing difficulties ^[13].

As the disease progresses, care goals are frequently re-evaluated, often shifting toward prioritizing comfort, social connection, and ease of daily care ^[14][15].